These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 24287322

  • 1. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC, Lin KJ, Hsiao IT, Hsieh CJ, Lin WY, Lu CS, Wey SP, Yen TC, Kung MP, Weng YH.
    J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
    [Abstract] [Full Text] [Related]

  • 2. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
    Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ.
    JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
    [Abstract] [Full Text] [Related]

  • 3. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
    Hsiao IT, Weng YH, Lin WY, Hsieh CJ, Wey SP, Yen TC, Kung MP, Lu CS, Lin KJ.
    Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
    [Abstract] [Full Text] [Related]

  • 4. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
    Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA.
    J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
    [Abstract] [Full Text] [Related]

  • 5. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ, Lin WY, Hsieh CJ, Weng YH, Wey SP, Lu CS, Skovronsky D, Yen TC, Chang CJ, Kung MP, Hsiao IT.
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [Abstract] [Full Text] [Related]

  • 6. Quantitative study of 18F-(+)DTBZ image: comparison of PET template-based and MRI based image analysis.
    Jung Lung H, Weng YH, Wen MC, Hsiao IT, Lin KJ.
    Sci Rep; 2018 Oct 30; 8(1):16027. PubMed ID: 30375444
    [Abstract] [Full Text] [Related]

  • 7. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
    Lin KJ, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Hsiao IT.
    PLoS One; 2013 Oct 30; 8(9):e75952. PubMed ID: 24098749
    [Abstract] [Full Text] [Related]

  • 8. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O'Keefe G, Jones G, Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC.
    J Nucl Med; 2010 Feb 30; 51(2):223-8. PubMed ID: 20080893
    [Abstract] [Full Text] [Related]

  • 9. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF.
    Nucl Med Biol; 2007 Apr 30; 34(3):239-46. PubMed ID: 17383573
    [Abstract] [Full Text] [Related]

  • 10. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
    Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA.
    Alzheimers Dement; 2008 Jan 30; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
    [Abstract] [Full Text] [Related]

  • 11. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
    Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, Ackermann U, O'Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky DM, Rowe CC.
    Arch Neurol; 2011 Jul 30; 68(7):905-12. PubMed ID: 21747030
    [Abstract] [Full Text] [Related]

  • 12. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF.
    Nucl Med Biol; 2006 Aug 30; 33(6):685-94. PubMed ID: 16934687
    [Abstract] [Full Text] [Related]

  • 13. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
    Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, Kung MP, Hsu CH, Wey SP.
    PLoS One; 2017 Aug 30; 12(3):e0173503. PubMed ID: 28257461
    [Abstract] [Full Text] [Related]

  • 14. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Ma JH, Dong C, Qiao HW, Barret O, Tamagnan GD, Mao W, Xu EH, Zhang C, Lu J, Chan P, Liu SY.
    Mov Disord; 2024 May 30; 39(5):847-854. PubMed ID: 38477228
    [Abstract] [Full Text] [Related]

  • 15. [18F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease.
    Weng CC, Huang SL, Chen ZA, Lin KJ, Hsiao IT, Yen TC, Kung MP, Wey SP, Hsu CH.
    Ann Nucl Med; 2017 Aug 30; 31(7):506-513. PubMed ID: 28451991
    [Abstract] [Full Text] [Related]

  • 16. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
    Huang CY, Liu CH, Tsao E, Hsieh CJ, Weng YH, Hsiao IT, Yen TC, Lin KJ, Huang CC.
    J Neurol Sci; 2015 Aug 30; 353(1-2):102-6. PubMed ID: 25936253
    [Abstract] [Full Text] [Related]

  • 17. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
    Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE.
    Ann Neurol; 1996 Dec 30; 40(6):873-84. PubMed ID: 9007092
    [Abstract] [Full Text] [Related]

  • 18. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Grafton ST, Kilts CD, Goodman MM.
    J Nucl Med; 2003 Jun 30; 44(6):855-61. PubMed ID: 12791810
    [Abstract] [Full Text] [Related]

  • 19. ¹⁸F-FP-(+)-DTBZ positron emission tomography detection of monoaminergic deficient network in patients with carbon monoxide related parkinsonism.
    Chang CC, Hsiao IT, Huang SH, Lui CC, Yen TC, Chang WN, Huang CW, Hsieh CJ, Chang YY, Lin KJ.
    Eur J Neurol; 2015 May 30; 22(5):845-52, e59-60. PubMed ID: 25690304
    [Abstract] [Full Text] [Related]

  • 20. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R, Zhang G, Chen X, Yang A, Smith G, Wong DF, Zhou Y.
    PLoS One; 2016 May 30; 11(10):e0164762. PubMed ID: 27764160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.